FRM-024 - Moligand™, 10 mM in DMSO , CAS No.2085780-87-4

CAS: 2085780-87-4 Cat. No.: F1494947 Formula: C₂₂H₂₂ClN₅O₂ Peso molecolare: 423.90

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Protected from light,Argon charged,Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease.

Specifications

Specifiche e purezza

Moligand™, 10 mM in DMSO

Condizioni di conservazione di stoccaggio

Protected from light,Argon charged,Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Tipo di azione

MODULATOR

Nomi e identificatori

• Peso molecolare: 423.90

Application Protocols

No manufacturer-validated application protocols are provided for FRM-024 in the current product data.

• Tested applications: Not specified for this item; refer to CoA/Spec Sheet.
• Recommended working concentrations, positive controls, and dilution guidelines: Not specified for this item; establish empirically for your assay.

Guidance:

• Develop and validate assay conditions specific to your target and readout. Include vehicle controls matching the co-solvent, verify solubility at intended concentrations, and assess stability over the assay timeframe under subdued light and minimal air exposure, consistent with the storage guidance.

For standardized, item-specific protocols (e.g., plate maps, dispensing instructions), contact Aladdin Scientific with your SKU and lot number.

Biological Roles

Item-specific biological function, target class, or pathway engagement for FRM-024 are not provided in the product data.

General context for Moligand-type screening compounds:

• Such compounds are designed/selected for physicochemical profiles amenable to biological screening (e.g., drug-like or fragment-like space). Their biological roles are not intrinsic but emerge from assay-dependent interactions with biomolecular targets (enzymes, receptors, ion channels, protein–protein interfaces).
• Depending on structure, compounds may act as reversible ligands, covalent binders, allosteric modulators, or chemical probes—however, no such behavior can be ascribed to FRM-024 without data.

Recommended practices:

• Establish mechanism-of-action only after orthogonal confirmation (biochemical vs biophysical vs cell-based).
• Check for common assay interferences (redox cycling, fluorescence/absorbance overlap, colloidal aggregation) before interpreting activity.
• If the compound is light- or oxygen-sensitive (suggested by storage conditions), include appropriate controls to discern authentic target engagement from decomposition artifacts.

Important: No medical or clinical claims are associated with this item. It is for research use only, and no endogenous biological role should be assumed in the absence of disclosed structure and validated bioactivity data.

Buffer Applications

This product is a small-molecule screening compound, not a buffering agent. No buffer capacity, pKa values, or buffer system applicability are provided.

• Buffer formulation roles: Not typically applicable. Select assay buffers (e.g., HEPES, PBS, Tris) based on your biological system, then introduce the compound via a compatible co-solvent (commonly low-% DMSO).
• Practical note (general): Validate compound stability in the chosen buffer at intended temperature, pH, and time scale. Include matched vehicle controls to isolate buffer effects from compound effects.

For any item-specific pKa or stability-in-buffer information, refer to the CoA/Spec Sheet, if available.

Green Alternatives

While the compound itself is fixed, the environmental footprint of its use is strongly influenced by solvent choice and assay design. Because item-specific solubility is not provided, consider greener practices during stock preparation and screening.

Greener solvent strategies (general):

• Prefer low-toxicity, biorenewable solvents for preparative steps where compatible. For dissolution, DMSO remains common; however, for washing/extraction steps consider bio-based ethanol or 2-methyltetrahydrofuran (2-MeTHF) when applicable to your workflow.

Miniaturization and waste reduction:

• Use low-dead-volume plates and acoustic dispensing to reduce DMSO and consumables waste.
• Consolidate control wells and adopt plate maps that minimize edge effects, thereby reducing repeat runs.

Comparison (general, literature):

• DMSO vs bio-ethanol for intermediate handling: DMSO offers broader solubility and stability for many drug-like molecules; ethanol is greener but can be too volatile and less solvating for lipophilic analytes.
• 2-MeTHF vs THF for preparative steps: 2-MeTHF (biorenewable, higher boiling, lower peroxide formation rate) is often preferred over THF, subject to compound compatibility.

Operational tips:

• Store concentrated DMSO stocks at low temperature to extend life and reduce decomposition; distribute in small aliquots to limit wastage.
• Employ closed, inerted systems to minimize operator exposure and emissions.

All solvent selections must be validated experimentally with your specific assay; the above are general sustainability guidelines.

Pharmaceutical Uses

FRM-024 is supplied strictly for research use only. No therapeutic, diagnostic, or clinical uses are claimed or supported.

Discovery and development context (general):

• Screening libraries such as Moligand™ are commonly employed in early drug discovery to identify hits for medicinal chemistry optimization. At this stage, compounds serve as tool molecules or starting points for structure–activity relationship (SAR) campaigns.
• The compound is not described as a pharmacopoeial excipient, and no formulation role is specified for clinical products.

Operational guidance:

• If transitioning from screening to preclinical research, ensure rigorous re-qualification of identity, purity, and stability under GLP-like practices.
• Establish synthetic resupply or purchase orthogonal batches before committing to advanced studies, and confirm impurity profiles to avoid false structure–activity attributions.

Item-specific regulatory status, GMP suitability, residual solvent limits, and impurity thresholds: Not specified for this item; refer to CoA/Spec Sheet and consult Aladdin Scientific if you require enhanced QC for regulated workflows.

Physical Properties

Item-specific physicochemical constants are not provided in the product data for FRM-024.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility in common solvents: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/general):

• Library members of this class are typically provided as neat solids or DMSO stocks. When neat, dissolution is often feasible in anhydrous DMSO, DMF, or ethanol before dilution into assay buffers.
• If aqueous work is required, co-solvent systems (e.g., 0.1–1% DMSO in buffer) are commonly used to maintain solubility; verify compatibility with the target assay.
• Hygroscopicity and photolability vary; this item is to be protected from light and stored under argon at −80 °C per product data, suggesting potential sensitivity to oxygen/moisture/light.

Always treat non-specified values as unknown until confirmed on the CoA/Spec Sheet or SDS.

Quality and Grades

• Grade: Moligand™ (as listed for FRM-024)

What Moligand™ typically entails (general explanation; not a specification):

• Moligand-designated compounds are curated for screening workflows, emphasizing confirmed identity and high chemical purity suited for biochemical and cell-based assays. Typical library QC often includes LC–MS identity confirmation and purity assessment, and, where applicable, 1H NMR verification. Acceptance criteria may be set to enable HTS/fragment screening usability (e.g., high purity and minimal interfering impurities), but exact thresholds are batch-dependent.

This item-specific notes:

• Exact purity percentage, residual solvent levels, elemental/metal analysis, water content, and stabilizers are Not specified for this item; refer to CoA/Spec Sheet.
• UV cutoff, extinction data, and chromatographic background are Not specified for this item; refer to CoA/Spec Sheet.

Implications for use:

• For analytical assays (SPR, DSF, enzymology, electrophysiology), confirm purity and counter-ion/solvent composition on the CoA to ensure clean baselines and accurate potency estimation.
• For cell-based work, verify endotoxin specifications if relevant to your application (not routinely included for small molecules).

Documentation:

• Retain batch CoA and SDS with your records. If you require additional QC (chiral purity, salt form, hydrate/solvate state), request it at order placement or perform in-house verification.

Reaction and Applications

This product is supplied as a Moligand™ small-molecule library member intended primarily for screening and target-engagement studies rather than as a synthetic reagent. No item-specific reactivity data or named-reaction roles are provided.

Research application contexts (general, non-exhaustive):

• Biochemical/biophysical screening: HTS, fragment-based screening (FBS/FBDD), thermal shift assays (DSF), differential scanning fluorimetry, surface plasmon resonance (SPR), microscale thermophoresis (MST), and isothermal titration calorimetry (ITC).
• Cell-based phenotypic assays: Reporter gene activity, viability/proliferation studies, morphology screens, and image-based profiling—using validated vehicle controls to manage DMSO exposure.
• Target deconvolution workflows: If a hit is obtained, follow-up with chemoproteomics, CETSA, or pull-down approaches may be pursued (assay development required).

Practical considerations (general):

• Confirm solubility and aggregation propensity (e.g., DLS or detergent-sensitive artifacts) before potency claims.
• Assess redox or photochemical liabilities given the storage guidance (argon, light protection), which can impact assay results.
• For SAR, procure orthogonal lots or analytical resupply to rule out lot-specific artifacts.

Note: No manufacturer-provided application expansion specific to FRM-024 is included in the product data. Treat the above as general guidance for Moligand-class compounds.

Reaction Conditions

Not typically applicable. FRM-024 is provided as a screening library compound, not a reagent or substrate for named organic reactions in this listing.

General note (if pursuing chemistry post-hit):

• Any reaction conditions for derivatization or scale-up are entirely structure-dependent. Common conditions for small-molecule modification might include cross-couplings (e.g., Pd-catalyzed) or amide couplings; however, such guidance would be speculative without the disclosed functional groups.

Actionable guidance:

• Defer reaction planning until you have the full structural and analytical package from the CoA/Spec Sheet. Verify stability to bases/acids, oxidants/reductants, and heat before attempting transformations.

Safety and Handling

Authoritative safety information resides in the product SDS. The following are general precautions because item-specific hazard data are not provided in this listing.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.

Handling guidance (general best practice):

• Use in a certified chemical fume hood with appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile).
• Avoid exposure to light and air; the item is supplied argon charged and should be handled under an inert atmosphere when feasible (e.g., argon or nitrogen purge) to maintain integrity.
• Prevent moisture ingress; keep containers tightly closed. Open only after thermal equilibration to minimize condensation.
• If supplied at cryogenic temperature (−80 °C), thaw gradually on ice or at 4 °C before opening to reduce pressure differentials and condensation.

Incompatibilities and risks (general):

• In the absence of structural data, avoid contact with strong oxidizers or reducing agents, strong acids/bases, and reactive metals.
• Do not heat or expose to UV sources unnecessarily; photolability is possible given the light-protection requirement.

First-aid overview (general):

• Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing.
• Inhalation: Move to fresh air; seek medical attention if symptoms persist.
• Ingestion: Rinse mouth; seek medical attention.

Always consult the SDS for batch-specific hazards and spill/fire-fighting procedures.

Solvent Selection

Item-specific solubility data are not provided. The guidance below reflects common practice for small-molecule screening compounds.

Primary stock preparation (general):

• DMSO is the default solvent for small-molecule libraries due to broad solvating power and compatibility with most biochemical and cell assays at ≤0.1–1% v/v final. Begin by attempting dissolution in anhydrous, oxygen-free DMSO.

Alternative solvents (general):

• If DMSO is suboptimal, consider DMF or ethanol for initial dissolution, then dilute into aqueous buffers. Maintain final co-solvent at the assay’s validated tolerance.
• For highly lipophilic compounds, co-solvent mixtures (e.g., DMSO + PEG400 or DMSO + ethanol) or inclusion of non-ionic surfactants at low ppm levels can be evaluated, subject to assay controls.

Assay buffer compatibility (general):

• Phosphate- or HEPES-based buffers typically tolerate low DMSO fractions; include matched vehicle controls. Avoid carbonate buffers if the compound is CO2- or base-sensitive.

Practical tips:

• Filter stocks only if solubility is confirmed; otherwise, use gentle warming and sonication to aid dissolution.
• Verify concentration by UV-Vis only if the molar absorptivity is known; otherwise, use gravimetric or quantitative NMR as appropriate.
• Protect from light during preparation per product guidance; pre-inert the vial headspace to minimize oxidation.

Do not treat any of the above as specifications; confirm solvent choices experimentally with your assay.

Storage and Reconstitution

Provided item-specific storage/shipping details:

• Storage conditions: Protected from light; Argon charged; Store at −80 °C.
• Shipped in: Dry ice packs + cold packs.
• Research use note: For research use only.

Best-practice handling (general guidance; not a specification):

• Upon receipt, keep the vial cold and protected from light. Allow the sealed container to equilibrate to 4 °C or room temperature before opening to minimize condensation.
• Maintain an inert gas blanket (argon or nitrogen) during transfers, especially if the compound is air- or moisture-sensitive as implied by argon charging.
• Reconstitution: If provided neat, dissolve initially in anhydrous, oxygen-free DMSO to prepare a concentrated primary stock. Mix gently; avoid vigorous vortexing if foaming is observed. If supplied as a DMSO stock, inspect for precipitation or phase separation after thawing and mix by gentle inversion.
• Aliquoting: Prepare single-use aliquots in inerted, amber vials or plates to limit light exposure and freeze–thaw cycles. Label with concentration, solvent, date, and lot.
• Storage of stocks: Return unused material promptly to −80 °C. Minimize time at ambient temperature and avoid repeated freeze–thaw to preserve integrity.
• Disposal: Follow institutional guidelines for organic chemical waste; do not discharge to drains.

Any item-specific concentration limits, aqueous stability, or shelf-life claims are Not specified for this item; consult the CoA/Spec Sheet and SDS for definitive instructions.

Structure and Identity

Brief description: FRM-024 (Moligand grade) is a research-only small-molecule library member supplied for screening and chemical biology applications. Detailed structural identifiers are not disclosed in the product data.

• SKU: F1494947
• Product name: FRM-024
• CAS: 2085780-87-4
• Category: Small molecules and compound libraries (Moligand™)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general note):

• Item-specific functional groups, ring systems, stereocenters, and electronic features are not provided in the current listing. Many Moligand-type library members are drug-like heteroaromatics or small fragments, but the precise features for FRM-024 are not disclosed here (do not infer without the CoA/SDS).
• 2D/3D structure description: Not available in the present data package. Obtain from the Certificate of Analysis or structure disclosure where applicable.

Identification guidance:

• Use the CAS number and SKU to cross-reference the batch CoA for exact identity metrics (structure drawing, LC–MS exact mass, NMR).
• If you require unambiguous structural information for computational screening or SAR, request the structure file (SDF/MOL) from the CoA, if provided for your library build.

Synthetic Utility

No structural information or functional group detail is provided for FRM-024, so its use as a synthetic building block or ligand in preparative chemistry cannot be assessed from the current data.

General considerations:

• Many screening compounds are fully elaborated small molecules rather than modular building blocks; they are typically used as test articles in assays, not as reagents or catalysts.
• If structure becomes available and contains handle(s) amenable to diversification (e.g., aryl halide, boronate, carboxylate, amine), the molecule could be adapted for SAR by late-stage functionalization (e.g., Suzuki–Miyaura, Buchwald–Hartwig, amide coupling). Such possibilities are strictly structure-dependent and cannot be inferred here.

Recommendation:

• For synthetic derivatization or bioconjugation plans, obtain the structural dossier (SDF/MOL, NMR, LC–MS) from the CoA and perform a retrosynthetic analysis to confirm feasibility and stability. Without that information, treat FRM-024 as a screening analyte rather than a synthetic intermediate.

Target Specificity

No target, pathway, or selectivity profile is provided for FRM-024 in the product data.

• Target class: Not specified for this item; refer to CoA/Spec Sheet or internal screening results.
• Species cross-reactivity: Not applicable to small molecules in the same way as for biologics; however, target homology across species should be considered when interpreting activity.

Recommendation:

• Establish specificity using orthogonal assays and counterscreens (e.g., related isoforms, off-target panels) and confirm with biophysical methods where feasible.

This section will remain blank of item-specific claims until target data are disclosed by the user’s own studies or by a provided data sheet.